Followers | 63 |
Posts | 8502 |
Boards Moderated | 0 |
Alias Born | 01/10/2014 |
Friday, January 17, 2020 10:45:29 AM
Oncolytics Biotech Inc ONCY:NASDAQ
Biotech Sector's Technological Advancements Winning Major Battles in the War on Cancer
PR Newswire
9:00 AM ET
USA News Group - In the war against cancer, it appears that all hands are on deck, with contributions coming from across the biotech sector. As the 2020s begin, new approvals and promising data are encouraging the market to pay more attention to the developers of new treatments, including Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), GlaxoSmithKline plc (NYSE:GSK), Aethlon Medical, Inc. (NASDAQ:AEMD), Clovis Oncology, Inc. (NASDAQ:CLVS), and Merck & Co., Inc. (NYSE:MRK).
Market researchers see big things to come from investment into the oncological war, with recent forecasts such as: the cancer gene therapy market surpassing $3.2 billion by 2026; the global breast cancer drug market offering a $40 billion opportunity; the noninvasive cancer diagnostics market hitting $195 billion by 2025; and the immunotherapy market estimated to reach $115 billion by 2023.
Key to the current optimism for drugs and therapies that are being developed, either from scratch or as enhancements.
PELAREOREP'S 1-2 COMBO PUNCH AGAINST CANCER
One thriving example an important enhancement therapy is pelareorep from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC)--an immuno-oncolytic virus (OV) being combined so me of the world's top selling anti-cancer drugs, including Keytruda ($7.2B in 2018 sales for Merck), Opdivo ($6.7B in 2018 sales for Bristol-Myers Squibb), Tecentriq ($766M in 2018 sales for Roche) and Bavencio ($75.5M in 2018 sales for Pfizer/Merck).
Recently Reuters published an analysis that revealed a record 89 therapies are currently undergoing human trials involving the pairing of treatments with antibodies with toxic agents to fight cancer--which Reuters calls "guided-missile" cancer drugs.
Like a guided missile, pelareorep selectively infects tumor cells, leading to the creation of inflamed tumors. T hese then engage the body's immune system to create of tumor reactive T cells.
This process is designed to enhance the likes of the market's best oncology drugs out there, as listed above. It does this by expanding existing T cell clones priming the immune system for checkpoint blockade. To date, the drug has synergized with all checkpoint inhibitor combinations tested.
So far, based on the final advice from the FDA following their EOP2 meeting, the company's been granted Special Protocol Assessment (SPA). It's been recommended that identification of biomarker should be done before Phase III. Confirmation of a single phase 3 study is required for approval.
Already across 13 clinical studies and a broad range of cancers, up to 96% of tumor samples tested positive for replicating pelareorep virus after intravenous delivery. To date, pelareorep is the only oncolytic virus with meaningful clinical data demonstrating intravenous delivery to tumor tissue.
To date, it's been used to treat 1,100 patients, over 900 of which were administered intravenously--So far, no maximum tolerated dose (MTD) has been reached.
Worldwide, Oncolytics Biotech Inc. (ONCY-ONC) has accumulated 398 patents issued, including 48 US and 21 Canadian, and more than 21 additional applications pending.
The reovirus issued patent claims cover compositions of matter comprising reovirus (through 2028 and extendable to 2033), and all pharmaceutical uses of it.
GUIDED MISSILE PARTNERSHIPS
Pharma giants, such as GlaxoSmithKline plc (NYSE:GSK), and Merck & Co., Inc. (NYSE:MRK) are throwing a lot of weight into these guided missile approaches--and there could be a lot more to come.
Between 2000 and 2018, US regulators only approved five antibody-drug conjugates (ADCs). In 2019, those same regulators approved three more, making it the largest one-year total ever. The tide is changing.
GlaxoSmithKline is currently testing its belantamab mafodotin against multiple myeloma. Most recently, the treatment's pivotal DREAMM-2 trial supported the drug's use for heavily-treated multiple myelom a.
Oncolytics Biotech Inc. (ONCY-ONC) has also recently highlighted pelareorep's unique ability to activate the immune system in late stage myeloma, with multiple myeloma data expected at ASCO 2020.
“Believing in negative thoughts is the single greatest obstruction to success.”
Charles F. Glassman
Statements made are only my opinion. Do your own DD in order to make your own investment decisions.
Recent ONCY News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/19/2024 11:01:30 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/06/2024 04:46:58 PM
- Sernova Corp. Announces Appointment of New Chief Executive Officer • GlobeNewswire Inc. • 08/12/2024 11:45:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/02/2024 09:11:26 PM
- Form SUPPL - Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] • Edgar (US Regulatory) • 08/02/2024 09:08:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/02/2024 12:40:34 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/02/2024 04:15:09 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/01/2024 08:54:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/01/2024 08:03:42 PM
- Form F-X - Appointment of Agent for Service of Process and Undertaking • Edgar (US Regulatory) • 07/25/2024 09:22:38 PM
- Form F-10 - Registration Statement for Securities of certain Canadian Issuers. • Edgar (US Regulatory) • 07/25/2024 08:48:54 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/24/2024 05:34:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/20/2024 04:04:42 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 05:47:53 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/16/2024 03:00:15 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/15/2024 11:06:37 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/09/2024 08:37:10 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/09/2024 08:36:25 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/09/2024 04:11:18 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 05:43:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 09:06:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 06:08:24 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2024 05:37:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 06:09:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/14/2024 01:30:16 PM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM